LDS/Medical Tests/Hepatitis B Virus (HBV) Antibody Panel for Acute and Chronic Infection

Hepatitis B Virus (HBV) Antibody Panel for Acute and Chronic Infection

Hepatitis B virus (HBV) is a member of *hepadnaviruses* and is the major cause of liver disease. Infection with HBV leads to a variety of conditions, including an asymptomatic chronic state, acute self-limiting infection, and fulminant hepatitis. Persistent HBV infection is strongly associated with hepatocellular carcinoma. Persons at greatest risk of acquiring HBV infection include: parenteral drug users, men and women with multiple sex partners, patients receiving plasma-derived products, infants born to HBV-infected mothers, and persons living in endemic areas. After a person is exposed to the virus, the serologic course of HBV infection begins approximately 6 to 10 weeks after exposure with the appearance of HBsAg and HBeAg, a marker of active HBV replication. HBV DNA may be detectable in serum up to 21 days before the appearance of HBsAg. Patients then exhibit increased serum aminotransferase levels, usually ≥ 500 U/L, with the serum alanine aminotransferase (ALT) typically higher than the aspartate aminotransferase (AST) level. Approximately 10 weeks after exposure to HBV, patients may develop nonspecific symptoms such as fatigue and malaise, as well as right upper quadrant pain and jaundice. At this time, antibody to hepatitis B core antigen (anti-HBc) of the IgM class appears in the serum. In the recovery phase of HBV infection, serum aminotransferase levels return to normal, HBeAg disappears and antibody to HBeAg (anti-HBe) appears in serum, and ultimately, HBsAg seroconversion to antibody to HBsAg (anti-HBs) occurs. IgM anti-HBc levels begin to decline as levels of anti-HBc of the IgG class rise in serum. Recovery from acute HBV infection is typically associated with undetectable serum levels of HBV DNA. The hallmark of progression to chronic HBV infection is the presence of HBsAg for more than 6 months. Typically, in the early, or replicative, phase of chronic HBV infection, markers of active viral replication, HBeAg and serum HBV DNA levels > 10^5 copies/mL, are present. Patients may ultimately enter a nonreplicative state characterized by seroconversion from HBeAg to anti-HBe, serum HBV DNA levels <10^5 copies/mL, and normalization of serum aminotransferase levels. This phase is also referred to as the inactive carrier state. It is important to note that up to 20% of patients in the inactive carrier state may experience a reactivation to the replicative state, or flare, and may even cycle between the nonreplicative and replicative states. Such flares are characterized by an increase in serum aminotransferase levels and serum HBV DNA levels to > 10^5 copies/mL, with or without seroreversion to HBeAg. Reappearance of HBeAg may or may not occur during reactivation. Prompt, accurate diagnosis is critical for assessing infectivity and evaluating the prognosis for HBV-infected individuals. Hepatitis serology testing can be used as an aid in the diagnosis of individuals with acute or chronic HBV infection, and evaluation of serologic conversion to determine immunity status following exposure or vaccination. Each HBV-related test may be ordered individually based on clinical indication and medical necessity.
Test Name: Clinical Utility IgM antibody to Hepatitis B core Antigen: Diagnosis of acute HBV infection. Hepatitis B Surface Antigen: Diagnosis of acute or chronic HBV infection and to monitor the status of infection. Screen for hepatitis B infection in pregnant women. Antibody to Hepatitis B Surface Antibody: Status of immunity to Hepatitis B following exposure or vaccination. Total Antibodies to Hepatitis B Core Antigen: Infection staging to be used in conjunction with other serology markers.
Antibody / Antigen Acute Chronic / Active Recovery / Exposure
HBV IgM Antibody + ± -
HBV Surface Antibody (HBsAb) - ± +
HBV Surface Antigen (HBsAg) ± + -
Total HBV Core Antibody - + +
HBV e-Antigen (HBeAg) + + -

 

Negative (Non-reactive) 
 

 

 

Enzyme immunoassay (EIA), ELISA.

Serum (SST), plasma (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Hepatitis C antibody, Hepatitis A Antibody, Comprehensive Metabolic Panel, Liver panel, Hepatitis B Viral Load (by PCR).
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login